Supplementary Information
endometrial cancer
ENDOMETRIAL CANCER
Second-line treatment of endometrial cancer is an unmet medical need. Lurbinectedin showed promising antitumor activity in a phase I study in combination with doxorubicin in advanced endometrial cancer. This phase 2 Basket trial evaluated lurbinectedin 3.2 mg/mThe online version contains supplementary material available at 10.1007/s10637-023-01383-2.